Alba Rocco, Costantino Sgamato, Filippo Pelizzaro, Vittorio Simeon, Pietro Coccoli, Debora Compare, Elisa Pinto, Giorgio Palano, Francesco Giuseppe Foschi, Giovanni Raimondo, Gabriele Missale, Gianluca Svegliati-Baroni, Franco Trevisani, Eugenio Caturelli, Maurizia Rossana Brunetto, Gianpaolo Vidili, Alberto Masotto, Donatella Magalotti, Claudia Campani, Antonio Gasbarrini, Francesco Azzaroli, Gian Ludovico Rapaccini, Bernardo Stefanini, Rodolfo Sacco, Andrea Mega, Edoardo Giovanni Giannini, Giuseppe Cabibbo, Mariella Di Marco, Maria Guarino, Paolo Chiodini, Fabio Farinati, Gerardo Nardone
{"title":"全身炎症反应标志物提高肝细胞癌预后模型的鉴别能力。","authors":"Alba Rocco, Costantino Sgamato, Filippo Pelizzaro, Vittorio Simeon, Pietro Coccoli, Debora Compare, Elisa Pinto, Giorgio Palano, Francesco Giuseppe Foschi, Giovanni Raimondo, Gabriele Missale, Gianluca Svegliati-Baroni, Franco Trevisani, Eugenio Caturelli, Maurizia Rossana Brunetto, Gianpaolo Vidili, Alberto Masotto, Donatella Magalotti, Claudia Campani, Antonio Gasbarrini, Francesco Azzaroli, Gian Ludovico Rapaccini, Bernardo Stefanini, Rodolfo Sacco, Andrea Mega, Edoardo Giovanni Giannini, Giuseppe Cabibbo, Mariella Di Marco, Maria Guarino, Paolo Chiodini, Fabio Farinati, Gerardo Nardone","doi":"10.1007/s12072-025-10806-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/purpose of the study: </strong>We aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and their combination (combined NLR-PLR, CNP) in predicting overall survival (OS) and recurrence-free survival (RFS) in a large cohort of unselected hepatocellular carcinoma (HCC) patients.</p><p><strong>Methods: </strong>Training and validation cohort data were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. The optimal cut-offs of NLR and PLR were calculated according to the multivariable fractional polynomial and the minimum p value method. The continuous effect and best cut-off categories of NLR and PLR were analyzed using multivariable Cox regression analysis. A shrinkage procedure adjusted over-fitting hazard ratio (HR) estimates of best cut-off categories. C-statistic and integrated discrimination improvement (IDI) were calculated to evaluate the discrimination properties of the biomarkers when added to clinical survival models.</p><p><strong>Results: </strong>2,286 patients were split into training (n = 1,043) and validation (n = 1,243) cohorts. The optimal cut-offs for NLR and PLR were 1.45 and 188, respectively. NLR (HR 1.58, 95% CI 1.11-2.28, p = 0.014) and PLR (HR 1.79, 95% CI 1.11-2.90, p = 0.018) were independent predictors of OS. When incorporated into a clinical prognostic model that includes age, alpha-fetoprotein (AFP), the CHILD-Pugh score, and the Barcelona Clinic Liver Cancer (BCLC) staging system, CNP had a significant incremental value in predicting OS (IDI 1.3%, p = 0.04). Data were confirmed in the validation cohort. Neither NLR nor PLR significantly predicted RFS in the training cohort.</p><p><strong>Conclusions: </strong>NLR, PLR, and CNP independently predicted shorter OS in HCC patients. The addition of CNP to the survival prediction model significantly improved the model's accuracy in predicting OS.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma.\",\"authors\":\"Alba Rocco, Costantino Sgamato, Filippo Pelizzaro, Vittorio Simeon, Pietro Coccoli, Debora Compare, Elisa Pinto, Giorgio Palano, Francesco Giuseppe Foschi, Giovanni Raimondo, Gabriele Missale, Gianluca Svegliati-Baroni, Franco Trevisani, Eugenio Caturelli, Maurizia Rossana Brunetto, Gianpaolo Vidili, Alberto Masotto, Donatella Magalotti, Claudia Campani, Antonio Gasbarrini, Francesco Azzaroli, Gian Ludovico Rapaccini, Bernardo Stefanini, Rodolfo Sacco, Andrea Mega, Edoardo Giovanni Giannini, Giuseppe Cabibbo, Mariella Di Marco, Maria Guarino, Paolo Chiodini, Fabio Farinati, Gerardo Nardone\",\"doi\":\"10.1007/s12072-025-10806-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/purpose of the study: </strong>We aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and their combination (combined NLR-PLR, CNP) in predicting overall survival (OS) and recurrence-free survival (RFS) in a large cohort of unselected hepatocellular carcinoma (HCC) patients.</p><p><strong>Methods: </strong>Training and validation cohort data were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. The optimal cut-offs of NLR and PLR were calculated according to the multivariable fractional polynomial and the minimum p value method. The continuous effect and best cut-off categories of NLR and PLR were analyzed using multivariable Cox regression analysis. A shrinkage procedure adjusted over-fitting hazard ratio (HR) estimates of best cut-off categories. C-statistic and integrated discrimination improvement (IDI) were calculated to evaluate the discrimination properties of the biomarkers when added to clinical survival models.</p><p><strong>Results: </strong>2,286 patients were split into training (n = 1,043) and validation (n = 1,243) cohorts. The optimal cut-offs for NLR and PLR were 1.45 and 188, respectively. NLR (HR 1.58, 95% CI 1.11-2.28, p = 0.014) and PLR (HR 1.79, 95% CI 1.11-2.90, p = 0.018) were independent predictors of OS. When incorporated into a clinical prognostic model that includes age, alpha-fetoprotein (AFP), the CHILD-Pugh score, and the Barcelona Clinic Liver Cancer (BCLC) staging system, CNP had a significant incremental value in predicting OS (IDI 1.3%, p = 0.04). Data were confirmed in the validation cohort. Neither NLR nor PLR significantly predicted RFS in the training cohort.</p><p><strong>Conclusions: </strong>NLR, PLR, and CNP independently predicted shorter OS in HCC patients. The addition of CNP to the survival prediction model significantly improved the model's accuracy in predicting OS.</p>\",\"PeriodicalId\":12901,\"journal\":{\"name\":\"Hepatology International\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12072-025-10806-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12072-025-10806-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
研究背景/目的:我们旨在评估中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)及其联合(NLR -PLR、CNP联合)在预测非选择性肝细胞癌(HCC)患者总生存期(OS)和无复发生存期(RFS)中的作用。方法:从意大利肝癌(ITA.LI.CA)数据库中检索训练和验证队列数据。根据多变量分数多项式和最小p值法,计算出NLR和PLR的最优截止值。采用多变量Cox回归分析NLR和PLR的连续效应和最佳截止类别。收缩程序调整了最佳截止类别的过度拟合风险比(HR)估计。计算c统计量和综合判别改善(IDI),以评估生物标志物加入临床生存模型时的判别特性。结果:2,286例患者被分为训练组(n = 1,043)和验证组(n = 1,243)。NLR和PLR的最佳临界值分别为1.45和188。NLR (HR 1.58, 95% CI 1.11-2.28, p = 0.014)和PLR (HR 1.79, 95% CI 1.11-2.90, p = 0.018)是OS的独立预测因子。当纳入包括年龄、甲胎蛋白(AFP)、CHILD-Pugh评分和巴塞罗那临床肝癌(BCLC)分期系统在内的临床预后模型时,CNP在预测OS方面具有显著的增加价值(IDI 1.3%, p = 0.04)。数据在验证队列中得到确认。NLR和PLR均不能显著预测训练队列的RFS。结论:NLR、PLR和CNP独立预测HCC患者较短的OS。在生存预测模型中加入CNP显著提高了模型预测OS的准确性。
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma.
Background/purpose of the study: We aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and their combination (combined NLR-PLR, CNP) in predicting overall survival (OS) and recurrence-free survival (RFS) in a large cohort of unselected hepatocellular carcinoma (HCC) patients.
Methods: Training and validation cohort data were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. The optimal cut-offs of NLR and PLR were calculated according to the multivariable fractional polynomial and the minimum p value method. The continuous effect and best cut-off categories of NLR and PLR were analyzed using multivariable Cox regression analysis. A shrinkage procedure adjusted over-fitting hazard ratio (HR) estimates of best cut-off categories. C-statistic and integrated discrimination improvement (IDI) were calculated to evaluate the discrimination properties of the biomarkers when added to clinical survival models.
Results: 2,286 patients were split into training (n = 1,043) and validation (n = 1,243) cohorts. The optimal cut-offs for NLR and PLR were 1.45 and 188, respectively. NLR (HR 1.58, 95% CI 1.11-2.28, p = 0.014) and PLR (HR 1.79, 95% CI 1.11-2.90, p = 0.018) were independent predictors of OS. When incorporated into a clinical prognostic model that includes age, alpha-fetoprotein (AFP), the CHILD-Pugh score, and the Barcelona Clinic Liver Cancer (BCLC) staging system, CNP had a significant incremental value in predicting OS (IDI 1.3%, p = 0.04). Data were confirmed in the validation cohort. Neither NLR nor PLR significantly predicted RFS in the training cohort.
Conclusions: NLR, PLR, and CNP independently predicted shorter OS in HCC patients. The addition of CNP to the survival prediction model significantly improved the model's accuracy in predicting OS.
期刊介绍:
Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL). This is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal will focus mainly on new and emerging technologies, cutting-edge science and advances in liver and biliary disorders.
Types of articles published:
-Original Research Articles related to clinical care and basic research
-Review Articles
-Consensus guidelines for diagnosis and treatment
-Clinical cases, images
-Selected Author Summaries
-Video Submissions